Smith & Nephew
About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Employees: 18,000
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
276% more call options, than puts
Call options by funds: $933K | Put options by funds: $248K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
26% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 31
21% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 68
2% more funds holding
Funds holding: 207 [Q3] → 211 (+4) [Q4]
0.34% more ownership
Funds ownership: 3.51% [Q3] → 3.84% (+0.34%) [Q4]
13% less capital invested
Capital invested by funds: $953M [Q3] → $826M (-$127M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Canaccord Genuity Caitlin Cronin 15% 1-year accuracy 2 / 13 met price target | 7%downside $27 | Hold Maintained | 17 Mar 2025 |
Canaccord Genuity Kyle Rose 40% 1-year accuracy 2 / 5 met price target | 7%downside $27 | Hold Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 11 articles about SNN published over the past 30 days









